| 產(chǎn)品編號 | 116812 |
| 品牌 | Sigma |
| 測定 | ≥98% (HPLC) |
| 顏色 | white |
| 形式 | solid |
| 警告 | Toxicity: Standard Handling (A) |
| 運(yùn)輸 | ambient |
| 溶解性 | water: 10?mg/mL |
| 分子量 | 493.79 |
| 儲存溫度 | ?20°C |
| 儲存條件 | OK to freeze
desiccated (hygroscopic) |
| 質(zhì)量水平 | 100 |
| MDL編號 | MFCD00057683 |
別名
Adenosine 3ʹ,5ʹ-cyclic Monophosphate, 8-(4-Chlorophenylthio)-, Sodium Salt - CAS 93882-12-3 - Calbiochem,Adenosine 3ʹ,5ʹ-cyclic Monophosphate, 8-(4-Chlorophenylthio)-, Sodium Salt
一般描述
Cell-permeable cAMP analog that activates both protein kinase A and protein kinase G. Directly activates Epac, a Rap1 guanine-nucleotide exchange factor. Also acts as a potent inhibitor of cGMP-specific phosphodiesterase (IC50 = 900 nM). Inhibits cAMP-specific phosphodiesterase at much higher concentrations (IC50 = 25 μM).
Cell-permeable cAMP analog that activates both protein kinase A and protein kinase G. Induces the guanine-nucleotide-exchange factor activity of EGFI, also known as Epac (exchange protein directly activated by cAMP), and EGFII towards Rap1 both in vivo and in vitro. Also acts as a potent inhibitor of cGMP specific phosphodiesterase (IC50 = 900 nM). Also inhibits cAMP-specific phosphodiesterases at much higher concentrations (IC50 = 25 μM).
生化/生理作用
Cell permeable: yes
Primary Target
Protein kinase A and protein kinase G
Product does not compete with ATP.
Reversible: no
Target IC50: 900 nM against cGMP-specific phosphodiesterase
重懸
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C
其他說明
de Rooij, J., et al. 1998. Nature.396, 474.
Kawasaki, H., et al. 1998. Science.282, 2275.
Moed, P.J., et al. 1993. Comp. Biochem. Physiol.105A, 711.
Connolly, B.J., et al. 1992. Biochem. Pharmacol.44, 2303.
Phillips, M.E., and Taylor, A. 1992. J. Physiol.456, 591.
Shipston, M.J., and Antoni, F.A. 1992. Endocrinology130, 2213.
Datta, R., et al. 1991. Blood78, 83.
Peters, D.J.M., et al. 1991. Proc. Natl. Acad. Sci. USA88, 9219.
Sandberg, M., et al. 1991. Biochem. J.279, 521.
Unterman, T.G., et al. 1991. Endocrinology128, 2693.
Xu, H., et al. 1989. Brain Res.504, 36.
關(guān)鍵字： Adenosine 3?,5?-cyclic Monophosphate, 8-(4-Chlorophenylthio)-, Sodium Salt - CAS 93882-12-3 - Calbiochem;Adenosine 3?,5?-cyclic Monophosphate, 8-(4-Chlorophenylthio)-, Sodium Salt - CAS 93882-12-3 - Calbiochem價格;Adenosine 3?,5?-cyclic Monophosphate, 8-(4-Chlorophenylthio)-, Sodium Salt - CAS 93882-12-3 - Calbiochem廠家;93882-12-3;Sigma
關(guān)于默克生命科學(xué)
我們擁有廣泛的高質(zhì)量產(chǎn)品組合和解決方案，致力于推動科學(xué)研究，提高藥物研發(fā)和生物制藥生產(chǎn)的質(zhì)量和效率，并為獲取準(zhǔn)確可靠的診斷和檢測結(jié)果提供安全的保障。我們的愿景是使全球各地的人們能夠更快地獲得提升人類健康水平的解決方案。我們的共同目標(biāo)是通過與全球科學(xué)界合作，解決生命科學(xué)中棘手的問題。
30萬個廣泛產(chǎn)品組合，其中包括業(yè)內(nèi)許多知名的品牌，Sigma-Alrdich?、Milli-Q?、 Supelco?、Millipore?、SAFC?和BioReliance?。
關(guān)于默克
是一家全球領(lǐng)先的科技公司，專注于醫(yī)藥健康、生命科學(xué)和電子科技三大領(lǐng)域。全球約有57,000名員工服務(wù)于默克，通過創(chuàng)造更加愉悅和可持續(xù)性的生活方式，為數(shù)百萬人的生活帶來積極的影響。從先進(jìn)的基因編輯技術(shù)和發(fā)現(xiàn)治療最具挑戰(zhàn)性疾病的獨(dú)特方法，到實現(xiàn)設(shè)備的智能化——默克無處不在。
科學(xué)探索和負(fù)責(zé)任的企業(yè)精神一直是默克科技進(jìn)步的關(guān)鍵，也是默克自1668年以來永葆活力的秘訣。默克家族作為公司的創(chuàng)始者至今仍持有默克大部分的股份，我們在全球都叫“默克”，僅美國和加拿大例外。默克的三大領(lǐng)域：醫(yī)藥健康、生命科學(xué)及電子科技在這兩個國家分別稱之為“EMD Serono”、“MilliporeSigma”和“EMD Electronics”。
默克在中國已經(jīng)有87年發(fā)展歷史，目前有超過4100名員工，在